ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA ResubmissionZacks Investment Research • 01/21/26
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder CancerBusiness Wire • 01/20/26
ImmunityBio Shares Surge on Updated Durable Lymphoma Study ResultsZacks Investment Research • 01/19/26
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over YearThe Motley Fool • 01/16/26
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/16/26
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphomaProactive Investors • 01/16/26
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom LymphomaBusiness Wire • 01/16/26
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCGBusiness Wire • 01/16/26
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%The Motley Fool • 01/15/26
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-yearBusiness Wire • 01/15/26
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/14/26
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-SituBusiness Wire • 01/14/26
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung CancerBusiness Wire • 01/13/26
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health SecurityBusiness Wire • 01/12/26
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”Business Wire • 12/29/25